| Literature DB >> 32302896 |
Alessandra Brambati1, Raymond Mario Barry1, Agnel Sfeir2.
Abstract
Mammalian cells have evolved multiple pathways to repair DNA double strand breaks (DSBs) and ensure genome stability. In addition to non-homologous end-joining (NHEJ) and homologous recombination (HR), cells evolved an error-prone repair pathway termed microhomology-mediated end joining (MMEJ). The mutagenic outcome of MMEJ derives from the activity of DNA polymerase theta (Polθ) - a multidomain enzyme that is minimally expressed in normal tissue but overexpressed in tumors. Polθ expression is particularly crucial for the proliferation of HR deficient cancer cells. As a result, this mutagenic repair emerged as an attractive target for cancer therapy, and inhibitors are currently in pre-clinical development. Here, we review the multifunctionality of this enigmatic polymerase, focusing on its role during DSB repair in mammalian cells and its impact on cancer genomes.Entities:
Year: 2020 PMID: 32302896 PMCID: PMC7230004 DOI: 10.1016/j.gde.2020.02.017
Source DB: PubMed Journal: Curr Opin Genet Dev ISSN: 0959-437X Impact factor: 5.578